Sa. Norman et al., Identification of transforming growth factor-beta 1-binding protein overexpression in carmustine-resistant glioma cells by mRNA differential display, CANCER, 89(4), 2000, pp. 850-862
BACKGROUND. The authors previously demonstrated the presence of cells in pr
imary human malignant gliomas that intrinsically are resistant to carmustin
e (BCNU). Numerous studies have identified mechanisms of therapy resistance
in these cells; however, the authors' work and that of others suggest that
additional mechanisms of resistance exist.
METHODS. The authors identified a glioma cell line that lacks detectable me
thylguanine methyltransferase expression and does not alter its expression
of glutathione-S-transferase-pi in response to BCNU chemotherapy. This cell
line was used in mRNA differential display experiments to identify genes i
nvolved in what to the authors' knowledge were previously undescribed mecha
nisms of resistance.
RESULTS. The overexpression of the gene encoding the transforming growth fa
ctor latency binding protein was demonstrated in glioma cells selected for
resistance to BCNU, compared with their parental unselected cells.
CONCLUSIONS. Transforming growth factor-beta 1 has pleiotropic functions in
transformed and normal cells. Although activation of TGF-beta 1 does not a
ppear to be a causative factor in BCNU resistance in the current study, it
may be involved in the growth of these resistant cells. (C) 2000 American C
ancer Society.